Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma

Brentuximab vedotin (BV) is an antibody–drug conjugate that has demonstrated effectiveness as a monotherapy for patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma via several clinical trials. Salvage chemotherapy followed by autologous or allogeneic hem...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishizawa, Kenichi, Yanai, Tomoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822829/
https://www.ncbi.nlm.nih.gov/pubmed/31392578
http://dx.doi.org/10.1007/s12325-019-01046-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822829/
https://www.ncbi.nlm.nih.gov/pubmed/31392578
http://dx.doi.org/10.1007/s12325-019-01046-w

Ejemplares similares